Foundation to Eradicate Duchenne
Goal of finding treatments and an ultimate cure for Duchenne Muscular Dystrophy
Based in VA
🤖
AI Overview
With $420K in lobbying spend across 29 quarterly filings, Foundation to Eradicate Duchenne is an active lobbying client. Their lobbying covers 4 issue areas. Active from 2019 to 2025.
$420K
Total Spend
7
Years Active
1
Firms Hired
7
Lobbyists Deployed
4
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2019 | $60K |
| 2020 | $60K |
| 2021 | $60K |
| 2022 | $60K |
| 2023 | $60K |
| 2024 | $60K |
| 2025 | $60K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Defense, Health Issues, Budget/Appropriations, MED
- •Research funding for Duchenne Muscular Dystrophy
Related Analysis
Related Investigations
The Defense Lobby
Defense contractors spend millions lobbying for contracts worth billions.
Lobbying vs. Federal Contracts
How lobbying spending correlates with contract awards.
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
The 22,000% ROI
When lobbying spending yields outsized returns.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
Similar Clients
National Community Pharmacists Association
$15.4M total spend
Infectious Diseases Society of America
$5.1M total spend
Accendra Health, INC. (Formerly "owens & Minor, INC.")
$4.3M total spend
Association of Organ Procurement Organizations
$2.0M total spend
Assn. of State and Territorial Health Officials
$2.0M total spend
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.